More

Key programme achievements in Jan-Jun 2024

54,761
Number of notified cases of all forms of TB
1,241
Number of MDR-TB cases that began second-line treatment
96%
% of TB patients who had an HIV test result recorded
88%
% of all forms of TB cases successfully treated

Key programme achievements in 2023

87%
% of all forms of TB cases successfully treated
92%
% of TB patients who had an HIV test result recorded
2,525
number of MDR-TB cases that began second-line treatment
125,954
number of notified cases of all forms of TB

Key programme achievements in 2022

87%
% of all forms of TB cases successfully treated
2,310
number of MDR-TB cases that began second-line treatment
87%
% of TB patients who had an HIV test result recorded
107,086
number of notified cases of all forms of TB

Key programme achievements in 2021

1,295
number of MDR-TB cases that began second-line treatment
88%
% of TB patients who had an HIV test result recorded
65,801
number of notified cases of all forms of TB

Key programme achievements in 2020

97.20%
% of laboratories showing adequate performance in External Quality Assessment
2,357
number of MDR-TB cases that began second-line treatment
97.03%
% of TB patients who had an HIV test result recorded
87.72%
% of all forms of TB cases successfully treated
100,963
number of notified cases of all forms of TB

Key programme achievements in 2019

97.4%
% of laboratories showing adequate performance in External Quality Assessment
2,581
number of MDR-TB cases that began second-line treatment
93.8%
% of TB patients who had an HIV test result recorded
87.5%
% of all forms of TB cases successfully treated
131,339
number of notified cases of all forms of TB

Key programme achievements in 2018

96.2%
% of laboratories showing adequate performance in External Quality Assessment
2,703
number of MDR-TB cases that began second-line treatment
92%
% of TB patients who had an HIV test result recorded
87%
% of all forms of TB cases successfully treated
133,909
number of notified cases of all forms of TB

Key programme achievements in 2017

95%
% of laboratories showing adequate performance in External Quality Assessment
2,666
number of MDR-TB cases that began second-line treatment
89%
% of TB patients who had an HIV test result recorded
87.6%
% of all forms of TB cases successfully treated
130,414
number of notified cases of all forms of TB

Key programme achievements in 2016

95%
% of laboratories showing adequate performance in External Quality Assessment
2,537
number of MDR-TB cases that began second-line treatment
80.93%
% of TB patients who had an HIV test result recorded
85%
% of bacteriologically confirmed TB cases successfully treated
137,404
number of notified cases of all forms of TB

Key programme achievements in 2015

93.4%
% of laboratories showing adequate performance in External Quality Assessment
2,207
Number of MDR-TB cases that began second-line treatment
64%
% of TB patients who had an HIV test result recorded
85%
% of bacteriologically confirmed TB cases successfully treated
140,669
Number of notified cases of all forms of TB

Key programme achievements in 2014

92%
% of laboratories showing adequate performance in External Quality Assessment
1,537
Number of MDR-TB cases that began second-line treatment
40%
% of TB patients who had an HIV test result recorded
85%
% of bacteriologically confirmed TB cases successfully treated
141,994
Number of notified cases of all forms of TB

Key programme achievements in 2013

94%
% of laboratories showing adequate performance in External Quality Assessment
667
Number of MDR-TB cases that began second-line treatment
9%
% of TB patients who had an HIV test result recorded
85%
% of bacteriologically confirmed TB cases successfully treated
142,170
Number of notified cases of all forms of TB

Key programme achievements in 2012

% of laboratories showing adequate performance in External Quality Assessment
442
Number of MDR-TB cases that began second-line treatment
% of TB patients who had an HIV test result recorded
85.6%
% of bacteriologically confirmed TB cases successfully treated
147,622
Number of notified cases of all forms of TB

Key programme achievements in 2011

% of laboratories showing adequate performance in External Quality Assessment
50
Number of MDR-TB cases that began second-line treatment
% of TB patients who had an HIV test result recorded
85.5%
% of bacteriologically confirmed TB cases successfully treated
142,303
Number of notified cases of all forms of TB

TB Programme at a glance

1. Goal:

To end the TB epidemic in Myanmar, indicated by fewer than 10 cases per 100,000 population by 2035, as per the National Tuberculosis Plan (2021-2025). A precise goal is to achieve a 50% reduction in TB incidence by 2025 compared with the 2015 baseline.

2. Target Group/Beneficiaries:

  • The entire population of Myanmar. To ensure universal accessibility of diagnosis services, targeted interventions of TB for the following populations are prioritised - Migrants, IDP camps, contacts, and detainees;
  • Population in hard-to-reach areas, urban slums, and ethnic areas; 
  • People living with HIV, children younger than five years of age, elderly and people with diabetes.

3. Objectives:

  • Progress towards achieving universal access to TB care and prevention;
  • Reach the unreached populations and accelerate a coordinated TB response;
  • Expand partnerships and community engagement and improve communications;
  • Strengthen systems and update policies for a multisectoral TB response;
  • Promote research and innovation and strengthen surveillance for program monitoring and evaluation.

4. Planned Activities:

  • Expanding quality TB screening and diagnostic services using chest X-ray followed by GeneXpert;
  • Increasing TB case notification and finding missing TB cases through active case-finding mobile clinics equipped with portable digital X-ray and computer-aided diagnosis followed by WHO-recommended molecular testing (GeneXpert or TrueNat);
  • Identifying and treating all forms of TB, including drug-resistant and nationwide scale-up of shorter Bpal/BpalM regimens with second-line drug sensitivity testing, and ensuring treatment adherence with psycho-social supports for patients;
  • Scaling up TB preventive therapy (TPT) with the provision of TPT to all eligible populations;
  • Undertaking joint TB/HIV programs and decentralizing integrated services for TB and HIV;
  • Intensifying targeted actions to reach all at-risk populations to ensure universal accessibility of diagnosis services, targeted interventions such as diabetes screening among TB patients, and pre-entry screening at major prisons;
  • Engaging all care providers, including NGOs and the private sector in TB response as well as mandatory TB notification;
  • Promoting and strengthening community engagement (enable community health workers/volunteers through CBOs, CSOs and EHOs to engage in TB case finding and management and supporting a network of community-based organisations);
  • Ensuring availability of essential human resources to recruit seconded staff work for DRTB clinical teams, active case-finding mobile teams, NTRL/BSL-3 laboratories, supply chain management and TB surveillance;
  • Strengthening procurement and supply systems for efficient care delivery;
  • Strengthening TB surveillance, monitoring and evaluation (transition of electronic data management system and strengthening data quality control measures).

TB Programme Achievements

Next Pause
2023

In 2023, amidst the political instability in the country which brought up many challenges in the way programmes were implemented, PR-UNOPS and its implementing partners continued to maintain TB case finding, diagnosis and treatment services so that the interventions were ensured not to be interrupted.

Read More
2022

In 2022, PR-UNOPS worked closely with the public sector service providers and sub-recipients to maintain TB prevention, care, and treatment services while undertaking COVID-19 infection control measures so that the interventions were ensured not to be interrupted. 

During the year, 107,086 (77% of the annual target) TB patients were notified and enrolled in treatment. The treatment success rate was 87% (97% of the target). 

Read More
2021

The cumulative results for 2021 are shown as a percentage of the annual target. TB–HIV indicators (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

Read More
2020

The cumulative results for 2020 are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

Read More
2019

The cumulative results for 2019 are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

Read More
2018

The cumulative results for 2018 are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

TB grant implementation has also shown progress, with 7 out of 18 reportable indicators either meeting or exceeding the annual targets by the end of 2018.

During the year, 133,909 (84% of the annual target) TB patients were notified and enrolled on treatment. The treatment success rate was 87 per cent.

Read More
2017

The cumulative results for Year 7 (NFM) are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

TB grant implementation has also shown progress, with 6 out of 14 reportable indicators either meeting or exceeding the annual targets by the end of 2017.

During the year, 130,414 (84% of the annual target) TB patients were notified and enrolled on treatment. The treatment success rate was 88 per cent.

Read More
2016

The cumulative results for Year 6 (NFM) are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

TB grant implementation has also shown progress, with five out of eight reportable indicators either meeting or exceeding the annual targets.

Read More
2015

The cumulative results for Year 5 (NFM) are shown as a percentage of the annual target. TB–HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by GFATM and other donors, while the others are funded by GFATM only.

Read More
2014

The cumulative results for 2014 are shown as a percentage of the annual target. TB/HIV indicator (collaborative sites) and MDR-TB treatment indicators are funded by “GFATM and other donors” while the others are funded by GFATM only.

Read More
2013

The cumulative results for 2013 are shown as a percentage of the annual target. TB/HIV indicator (collaborative sites) is funded by “GFATM and other donors” while the others are funded by GFATM only.

Read More
2012

The cumulative results in each period during Year 2 are shown as a percentage of the annual target. Sex Workers, MSM and IDUs reached are funded by the Global Fund only, while the others are funded by "GFATM and other donors"

Read More
2011

The cumulative results in each period (P1-P4) are shown against the annual targets in percentages. TB/HIV (TB/HIV Collaborative Sites) indicator is funded by "GFATM and other donors" while the rest are funded by the Global Fund only.

Read More